Abstract: An anti-stress composition having for its active ingredient astaxanthin and/or its ester. This composition can be in the form of a pharmaceutical, functional food, food or beverage and so forth.
Abstract: The present invention provides methods and products for inhibiting neutrophil adhesion and neutrophil aggregation. The invention includes a method for treating a subject to inhibit neutrophil adhesion and neutrophil aggregation by administering 16-hydroxyeicosatetraenoic acid (16-HETE) to the subject. 16-HETE is an arachidonic acid metabolite. The invention also includes a pharmaceutical preparation of 16-HETE. Methods and products are also provided for treating thromboembolic stroke. The method involves the administration of 16-HETE in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke. Preferably, the 16-HETE is 16(R)-HETE and the thrombolytic agent is tPA. The product is a pharmaceutical preparation of 16-HETE and a thrombolytic agent and a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
November 26, 1999
Date of Patent:
October 31, 2000
Assignees:
The University of Vermont and State Agricultural College, New York Medical College, Board of Regents The University of Texas System
Inventors:
John R. Falck, Martin M. Bednar, Cordell E. Gross, Michael Balazy